ERBB2 and neoplasm: creatively designed a two‐region chimeric antigen receptor for macrophages as the adoptive macrophage therapy to target tumor tissues and destroy natural ECM physical barriers (Figure 2A,B).[94] The extracellular region of the chimeric antigen receptor was able to target breast cancer biomarker human epidermal growth factor receptor 2 (HER2), endowing macrophages with tumor targeting ability.